Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) Beneish M-Score: -2.70 (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02566 Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd HKSE:02566
20 GF Score
Price HK$5.41
! 1 Warning Sign
View Full Analysis

What is Hangzhou Jiuyuan Genetic Biopharmaceutical Co Beneish M-Score?

Hangzhou Jiuyuan Genetic Biopharmaceutical Co HKSE:02566 +3.05% 20 Beneish M-Score is -2.70 as of Aug. 16, 2026. GuruFocus rates HKSE:02566 with a GF Score™ of 20/100. The stock has 1 warning sign investors should review. Among 821 Biotechnology companies, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks better than 65.41% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.7 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Beneish M-Score or its related term are showing as below:

HKSE:02566' s Beneish M-Score Range Over the Past 10 Years
Min: -2.7   Med: -2.26   Max: -2.07
Current: -2.7

During the past 5 years, the highest Beneish M-Score of Hangzhou Jiuyuan Genetic Biopharmaceutical Co was -2.07. The lowest was -2.70. And the median was -2.26.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Beneish M-Score Chart

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
0.00 0.00 -2.26 -2.07 -2.70

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial -2.26 0.00 -2.07 0.00 -2.70

HKSE:02566 vs VRTX, REGN, RVMD: Beneish M-Score Comparison

For the Biotechnology subindustry, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Beneish M-Score falls into.


HKSE:02566
20GF Score
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd HKSE:02566
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Hangzhou Jiuyuan Genetic Biopharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9953+0.528 * 0.9791+0.404 * 1.1995+0.892 * 0.9872+0.115 * 0.9951
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9573+4.679 * -0.054973-0.327 * 1.0622
=-2.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was HK$669 Mil.
Revenue was HK$1,443 Mil.
Gross Profit was HK$1,164 Mil.
Total Current Assets was HK$1,638 Mil.
Total Assets was HK$2,340 Mil.
Property, Plant and Equipment(Net PPE) was HK$471 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$49 Mil.
Selling, General, & Admin. Expense(SGA) was HK$605 Mil.
Total Current Liabilities was HK$367 Mil.
Long-Term Debt & Capital Lease Obligation was HK$124 Mil.
Net Income was HK$153 Mil.
Gross Profit was HK$0 Mil.
Cash Flow from Operations was HK$282 Mil.
 Total Receivables was HK$681 Mil.
Revenue was HK$1,462 Mil.
Gross Profit was HK$1,155 Mil.
Total Current Assets was HK$1,505 Mil.
Total Assets was HK$2,053 Mil.
Property, Plant and Equipment(Net PPE) was HK$379 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$39 Mil.
Selling, General, & Admin. Expense(SGA) was HK$641 Mil.
Total Current Liabilities was HK$365 Mil.
Long-Term Debt & Capital Lease Obligation was HK$41 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(668.795 / 1443.104) / (680.652 / 1461.84)
=0.463442 / 0.465613
=0.9953

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1154.878 / 1461.84) / (1164.45 / 1443.104)
=0.790017 / 0.806907
=0.9791

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1638.485 + 470.959) / 2339.777) / (1 - (1505.39 + 379.271) / 2053.157)
=0.098442 / 0.082067
=1.1995

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1443.104 / 1461.84
=0.9872

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(39.439 / (39.439 + 379.271)) / (49.239 / (49.239 + 470.959))
=0.094192 / 0.094654
=0.9951

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(605.27 / 1443.104) / (640.5 / 1461.84)
=0.419422 / 0.438146
=0.9573

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((124.476 + 367.201) / 2339.777) / ((41.393 + 364.808) / 2053.157)
=0.210138 / 0.197842
=1.0622

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(152.902 - 0 - 281.527) / 2339.777
=-0.054973

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co has a M-score of -2.70 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.70 mean?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a Beneish M-Score of -2.70 as of Aug. 16, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors. According to the industry distribution chart, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks #284 out of 821 companies in the Biotechnology industry, placing it in the top 34.6%.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Beneish M-Score too high?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Beneish M-Score is -2.70. Based on the distribution chart, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks #284 out of 821 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hangzhou Jiuyuan Genetic Biopharmaceutical Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks #284 out of 821 companies for Beneish M-Score. This puts Hangzhou Jiuyuan Genetic Biopharmaceutical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Beneish M-Score is -2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co stock overvalued right now?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a current Beneish M-Score of -2.70. The current Beneish M-Score is -2.70. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566), the current Beneish M-Score is -2.70 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Business Description

Address No. 23, Eighth Street, Baiyang Street, Qiantang District, Zhejiang Province, Hangzhou, CHN
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, it has built a diversified product portfolio comprising several marketed products, such as Jilifen, Jijufen, Jiouting, Yinuojia, Guyoudao, etc., and has several product candidates under development, such as JY54, JY23, JY47, JY56, JY29-2, etc., targeting various indications. Geographically, the company generates maximum revenue from the Chinese Mainland, and the rest from other countries.
20GF Score

Get the complete analysis for HKSE:02566

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$5.41
Price